Innovative Strategies for Combating Multidrug-Resistant Tuberculosis: Advances in Drug Delivery Systems and Treatment
Microorganisms · 24.03.2025 · 13 (4) · 722
DOI: 10.3390/microorganisms13040722 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microorganisms, online erschienen am 24.03.2025. Verfasst von Omobolanle A Omoteso und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmaceutics, Faculty of Pharmacy, Rhodes University, Makhanda 6139, South Africa. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 227 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Rhodes University.
Abstract (Originalsprache)
Multidrug-resistant tuberculosis (MDR-TB) is a significant public health challenge globally, exacerbated by the limited efficacy of existing therapeutic approaches, prolonged treatment duration, and severe side effects. As drug resistance continues to emerge, innovative drug delivery systems and treatment strategies are critical to combating this crisis. This review highlights the molecular mechanisms underlying resistance to drugs in Mycobacterium tuberculosis, such as genetic mutation, efflux pump activity, and biofilm formation, contributing to the persistence and difficulty in eradicating MDR-TB. Current treatment options, including second-line drugs, offer limited effectiveness, prompting the need for innovation of advanced therapies and drug delivery systems. The progression in drug discovery has resulted in the approval of innovative therapeutics, including bedaquiline and delamanid, amongst other promising candidates under investigation. However, overcoming the limitations of traditional drug delivery remains a significant challenge. Nanotechnology has emerged as a promising solution, with nanoparticle-based drug delivery systems offering improved bioavailability and targeted and controlled release delivery, particularly for pulmonary targeting and intracellular delivery to macrophages. Furthermore, the development of inhalable formulations and the potential of nanomedicines to bypass drug resistance mechanisms presents a novel approach to enhancing drug efficacy. Moreover, adjunctive therapies, including immune modulation and host-directed therapies, are being explored to improve treatment outcomes. Immunotherapies, such as cytokine modulation and novel TB vaccines, offer complementary strategies to the use of antibiotics in combating MDR-TB. Personalized medicine approaches, leveraging genomic profiling of both the pathogen and the host, offer promise in optimizing treatment regimens and minimizing drug resistance. This review underscores the importance of multidisciplinary approaches, combining drug discovery, advanced delivery system development, and immune modulation to address the complexities of treating MDR-TB. Continued innovation, global collaboration, and improved diagnostics are essential to developing practical, accessible, and affordable treatments for MDR-TB.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pharmaceutics, Faculty of Pharmacy, Rhodes University, Makhanda 6139, South Africa.
- Department of Anesthesia, Division of Pain Management, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
ORCID-Profile: Omobolanle A Omoteso, Roderick B Walker, Sandile M Khamanga
Förderung
- Rhodes University
Zitieren
APA
Omoteso, O. A., Fadaka, A. O., Walker, R. B., & Khamanga, S. M. (2025). Innovative Strategies for Combating Multidrug-Resistant Tuberculosis: Advances in Drug Delivery Systems and Treatment. Microorganisms, 13(4), 722. https://doi.org/10.3390/microorganisms13040722
Vancouver
Omoteso OA, Fadaka AO, Walker RB, Khamanga SM. Innovative Strategies for Combating Multidrug-Resistant Tuberculosis: Advances in Drug Delivery Systems and Treatment. Microorganisms. 2025;13(4):722. doi:10.3390/microorganisms13040722
BibTeX
@article{Omoteso2025,
author = {Omoteso, Omobolanle A and Fadaka, Adewale O and Walker, Roderick B and Khamanga, Sandile M},
title = {Innovative Strategies for Combating Multidrug-Resistant Tuberculosis: Advances in Drug Delivery Systems and Treatment},
journal = {Microorganisms},
year = {2025},
volume = {13},
number = {4},
pages = {722},
doi = {10.3390/microorganisms13040722}
}
EUVIMED